WEGOVY® (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity.
WEGOVY® (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.
to reduce excess body weight and maintain weight reduction long term in:
Adults and pediatric patients aged 12 years and older with obesity
Adults with overweight in the presence of at least one weight-related comorbid condition.
Limitations of Use:
Co-administration with other semaglutide-containing products or any GLP-1 receptor agonist is not recommended.
The safety and efficacy of coadministration with other products for weight management have not been established.
There is limited experience from clinical trials with WEGOVY® in patients with a history of pancreatitis. It is unknown if patients with a history of pancreatitis are at a higher risk for development of pancreatitis on WEGOVY® .
